Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2025)
Roivant Sciences (ROIV) reported Income from Continuing Operations of 313701000.0 for Q4 2025, down 50.14% on a YoY basis from 629109171.27 in Q4 2024, and down 88.93% quarter-over-quarter from 166039000.0 in Q3 2025.
Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Roivant Sciences has reported Income from Continuing Operations for 6 years, with the latest figure at 313701000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 50.14% year-over-year to 313701000.0; the trailing twelve-month figure through Dec 2025 stood at 962596000.0 (down 120.68% YoY), and the FY2026 full-year result was 397907000.0, up 45.47% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 313701000.0, down from 166039000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5131180000.0 in Q4 2023, with the low at 384896000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 109349933.33 across 5 years, with a median of 244642000.0 in 2023.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 1167.12% — and 2023, when it surged 1433.13%.
- Roivant Sciences' Income from Continuing Operations stood at 306085000.0 in 2021, then decreased by 25.75% to 384896000.0 in 2022, then surged by 1433.13% to 5131180000.0 in 2023, then plunged by 104.07% to 208945000.0 in 2024, then tumbled by 50.14% to 313701000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 313701000.0 (Q4 2025), 166039000.0 (Q3 2025), and 273911000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -313.70 Mn |
| Sep 30, 2025 | -166.04 Mn |
| Jun 30, 2025 | -273.91 Mn |
| Dec 31, 2024 | -208.95 Mn |
| Sep 30, 2024 | -236.84 Mn |
| Jun 30, 2024 | -31.60 Mn |
| Dec 31, 2023 | 5.13 Bn |
| Sep 30, 2023 | -244.64 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -384.90 Mn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -306.09 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |